VBI Vaccines Announced The First Patients Have Been Dosed In Phase 2B Study Of VBI's Cancer Vaccine Immunotherapeutic Candidate, Vbi-1901 For First Recurrent Glioblastoma; Interim Data Analysis Expected Mid-year 2024, Subject To Speed Of Enrollment
Portfolio Pulse from Benzinga Newsdesk
VBI Vaccines has announced that the first patients have been dosed in a Phase 2B study of its cancer vaccine immunotherapeutic candidate, VBI-1901, for first recurrent glioblastoma. Interim data analysis is expected mid-year 2024, subject to the speed of enrollment.
September 07, 2023 | 12:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
VBI Vaccines has started a Phase 2B study of its cancer vaccine, VBI-1901. This could potentially impact the company's stock positively if the study shows promising results.
The initiation of a Phase 2B study for VBI Vaccines' cancer vaccine candidate, VBI-1901, is a significant step in the company's product development. If the study shows promising results, it could potentially lead to regulatory approval and commercialization, which would positively impact the company's revenues and stock price. However, the results are not expected until mid-2024, and the impact on the stock price will depend on the speed of enrollment and the interim data analysis.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100